Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 15/20 | 0.45 |
| ▸ | SMC2 | O95347 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.42 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.42 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391378 | 1.00 | MAP2K1 (0.45) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 | |
| SCHEMBL391769 | 0.90 | KCNH2 (0.45) | MAP2K1CSNK2A2MAP2K2KCNH2MAPK1 | |
| SCHEMBL391768 | 0.90 | KCNH2 (0.45) | MAP2K1CSNK2A2MAP2K2KCNH2MAPK1 | |
| SCHEMBL391890 | 0.89 | MAP2K1 (0.58) | MAP2K1MAP2K2KCNH2 | |
| SCHEMBL391889 | 0.89 | MAP2K1 (0.58) | MAP2K1MAP2K2KCNH2 | |
| SCHEMBL393664 | 0.87 | MAP2K1 (0.56) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 | |
| SCHEMBL12021813 | 0.81 | MAP2K1 (0.43) | MAP2K1SMC2EGFRCSNK2A2MAP2K2 | |
| SCHEMBL391796 | 0.81 | MAP2K1 (0.56) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL391795 | 0.81 | MAP2K1 (0.56) | MAP2K1MAP2K2MAPK1 | |
| SCHEMBL393213 | 0.81 | KCNH2 (0.57) | MAP2K1MAP2K2KCNH2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101611-B2 | Substituted pyridazines inhibitors of MEK | ARRAY BIOPHARMA INC. (US) | 2012-01-24 | — | — | US | claimed |
| US-20110183981-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-07-28 | — | — | US | claimed |
| US-20100063053-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-03-11 | — | — | US | claimed |
| EP-1967516-B1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2009-11-04 | — | — | EP | claimed |
| EP-1967516-A1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | Array Biopharma, Inc. (US) | 2008-09-10 | — | — | EP | claimed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | claimed |
| EP-2364973-B1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2014-07-09 | — | — | EP | disclosed |
| EP-2361905-B1 | Heterocyclic Inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8299076-B2 | crystalline form of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; for hyperproliferative diseases, such as cancer and inflammation in mammals; crystallization under acidic condition | ARRAY BIOPHARMA INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299076-B2 | crystalline form of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; for hyperproliferative diseases, such as cancer and inflammation in mammals; crystallization under acidic condition | ARRAY BIOPHARMA INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299076-B2 | crystalline form of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide; for hyperproliferative diseases, such as cancer and inflammation in mammals; crystallization under acidic condition | ARRAY BIOPHARMA INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8101611-B2 | Substituted pyridazines inhibitors of MEK | ARRAY BIOPHARMA INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101611-B2 | Substituted pyridazines inhibitors of MEK | ARRAY BIOPHARMA INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | ARRAY BIOPHARMA, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1967516-A1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | Array Biopharma, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| EP-1967516-A1 | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases | Array Biopharma, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2007044084-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112038-A1 | Heterocyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, MAPK9 | MAP2K1 73/4885SMC2 3924/4885EGFR 249/4885 |
| US-20080280957-A1 | Heterocyclic Inhibitors of Mek and Methods of Use Thereof | BRAF, NRAS, MAP3K1 | MAP2K1 51/4885SMC2 3777/4885EGFR 668/4885 |
| US-20100063053-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 73/4885SMC2 3924/4885EGFR 249/4885 |
| US-20110183981-A1 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | NRAS, BRAF, MAPK9 | MAP2K1 82/4885SMC2 3935/4885EGFR 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.